29th January 2019
From Portugal and Hungary
InnoStars extends a warm welcome to its two newest partners, Bluepharma of Portugal and CRU Hungary.
Bluepharma is a Portuguese capital pharmaceutical company, based in Coimbra. The Bluepharma group is today one of the most entrepreneurial and innovative in the pharmaceutical sector, having already achieved a remarkable prestige not only in Portugal, but also in the most demanding international markets.
The company concentrates its efforts on the manufacturing, development and marketing of pharmaceutical drugs.
With over 30 years of experience in producing pharmaceutical products, Bluepharma’s activities are carried out in 3 distinct areas: Research, development and registration of pharmaceutical drugs; Producing pharmaceutical drugs; Marketing of generic pharmaceuticals.
CRU was established in Hungary in 2008, focusing on clinical research services (Phase II-IV). Over time, the clinical research activities were extended to the earliest human phase, to Phase I trials, and nowadays CRU is one of the biggest and most active Phase I unit in the CEE region.
Apart from the clinical research extensions, new projects have been initiated in the recent years in the field of basic research such as Biobanking, Biomarker Research, Lipidomics, Proteomics and tumour genetics. CRU has research sites and/or offices in Hungary, Germany, Ukraine, Vietnam and Singapore. New sites are planned to be established in 2019 in Lao PDR, Thailand, Indonesia and Portugal.
- Cláudia Silva, Chief Scientific Officer at Bluepharma, email: firstname.lastname@example.org
- Dr Peter Kovacs, CEO and Managing Director of CRU Hungary Ltd., email: email@example.com
EIT Health helps Tubulis secure €10.7M in funding
Investor Network aids firm doing antibody work
EIT Health-backed start-ups garner big investments
A million each for iLoF and Restorative Neurotechnologies
EIT Health aids 11 start-ups disrupted by COVID-19
Start-up Rescue Instrument gives €5.5M in co-investment